Under the Cognita Imaging framework, radiologists will review discrepancies when there are clinically significant disagreements between the AI-generated report, the LLM jury, or the original radiologist's report.

Overview Debates Related claims Topics Sources

UCLA investigators developed MAESTRO, an artificial intelligence platform using large language models to analyze scientific knowledge and identify drug combinations that overcome cancer treatment resistance.

MAI-DxO works with different underlying language models, achieving its highest diagnostic performance using OpenAI's GPT-5 and GPT-5.5.

In the Science study, 304 complex cases published in the New England Journal of Medicine were evaluated without physical examinations or medical imaging available to the AI or human doctors.

Researchers measured how effectively MAI-DxO selected diagnostic tests rather than evaluating only final diagnostic accuracy.

Doctors should be allowed to prescribe undisclosed placebos when no effective treatment exists

The psychological effect on a patient of receiving a drug prescribed by a doctor is beneficial in itself

President Donald Trump nominated wellness influencer Dr. Casey Means for surgeon general, but her nomination was withdrawn after Senate confirmation stalled over concerns regarding her medical experience and vaccine stances

In an October 22, 2026 statement announcing his resignation, Calley Means, a senior adviser to Health and Human Services Secretary Robert F. Kennedy Jr., expressed tremendous respect for President Donald Trump and Kennedy without stating a reason

Calley Means and his statement on October 22, 2026 highlighted Make America Healthy Again policy achievements, including expanding access to psychedelics, overhauling dietary guidelines, and limiting SNAP benefits for sugary drinks

While serving at the Department of Health and Human Services, Calley Means attacked leading physician groups, federal agencies, and government scientists, claiming they protect their own interests

The United States Medicaid program faces nearly $1 trillion in federal funding cuts over the coming decade

Approximately 25% of new prescription drugs launched in the U.S. in 2025 had annual net prices exceeding $500,000, while another 34% were priced between $200,000 and $500,000.

The median net launch price of newly approved U.S. prescription drugs rose 35% after adjusting for inflation, increasing from $190,000 in 2022 to $257,000 in 2025, according to a report by ICER and West Health.

Donald Trump has formed more than a dozen deals asking drugmakers to adopt most-favored nation drug pricing in exchange for tariff relief.

The median list price for newly approved U.S. prescription drugs, adjusted for inflation, rose 24% from 2022 to $293,000 in 2025.

Two-thirds of newly approved prescription drugs reviewed by the Institute for Clinical and Economic Review between 2022 and 2025 were launched at prices exceeding ICER's cost-effectiveness thresholds.

Four in 10 prescription claims for the 26 new medicines reviewed by ICER between 2022 and 2025 were rejected by health insurers.

PhRMA spokesperson Chanse Jones acknowledged that coverage rejections and administrative hurdles by insurers delay and deny patient access to new treatments.

The Institute for Clinical and Economic Review suggested drug manufacturers may be raising launch prices to maximize profits before government Medicare price negotiations and most-favored nation pricing deals take effect.

An August 2026 draft report by ICER found that new aldosterone synthase inhibitor hypertension drugs cost between $833,000 and $2.08 million per quality-adjusted life year gained compared with generic alternatives.